40
Participants
Start Date
October 16, 2024
Primary Completion Date
July 1, 2025
Study Completion Date
July 1, 2027
DEB-TACE
"DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells."
RECRUITING
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Collaborators (1)
Boston Scientific Corporation
INDUSTRY
RenJi Hospital
OTHER